Nabriva Therapeutics (NBRV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock NBRV vs. FBRX, PLX, MIST, AVTX, TARA, CTOR, IPHA, NLTX, SLS, and MCRBShould you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Forte Biosciences (FBRX), Protalix BioTherapeutics (PLX), Milestone Pharmaceuticals (MIST), Avalo Therapeutics (AVTX), Protara Therapeutics (TARA), Citius Oncology (CTOR), Innate Pharma (IPHA), Neoleukin Therapeutics (NLTX), SELLAS Life Sciences Group (SLS), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry. Nabriva Therapeutics vs. Its Competitors Forte Biosciences Protalix BioTherapeutics Milestone Pharmaceuticals Avalo Therapeutics Protara Therapeutics Citius Oncology Innate Pharma Neoleukin Therapeutics SELLAS Life Sciences Group Seres Therapeutics Forte Biosciences (NASDAQ:FBRX) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Do analysts prefer FBRX or NBRV? Forte Biosciences currently has a consensus price target of $68.00, suggesting a potential upside of 366.39%. Given Forte Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Forte Biosciences is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is FBRX or NBRV more profitable? Forte Biosciences has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Forte Biosciences' return on equity of -85.38% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -85.38% -72.34% Nabriva Therapeutics -148.11%-365.53%-135.81% Does the media refer more to FBRX or NBRV? In the previous week, Forte Biosciences had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 2 mentions for Forte Biosciences and 0 mentions for Nabriva Therapeutics. Forte Biosciences' average media sentiment score of 0.85 beat Nabriva Therapeutics' score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the media. Company Overall Sentiment Forte Biosciences Positive Nabriva Therapeutics Neutral Do insiders & institutionals hold more shares of FBRX or NBRV? 77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher earnings and valuation, FBRX or NBRV? Forte Biosciences has higher earnings, but lower revenue than Nabriva Therapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$35.48M-$16.29-0.90Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A Which has more risk & volatility, FBRX or NBRV? Forte Biosciences has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. SummaryForte Biosciences beats Nabriva Therapeutics on 13 of the 15 factors compared between the two stocks. Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBRV vs. The Competition Export to ExcelMetricNabriva TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.46M$1.02B$9.07B$10.57BDividend YieldN/A4.84%5.69%4.71%P/E Ratio0.001.2685.9127.39Price / SalesN/A142.99536.12199.89Price / CashN/A17.6437.9261.55Price / BookN/A7.3613.006.76Net Income-$57.19M-$7.88M$3.30B$275.79M Nabriva Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070FBRXForte Biosciences3.0724 of 5 stars$15.00+3.6%$68.00+353.3%+193.3%$180.03MN/A-0.925Analyst ForecastPLXProtalix BioTherapeutics1.9822 of 5 stars$2.22+2.8%$15.00+575.7%+154.5%$177.01M$61.95M-17.08200Positive NewsMISTMilestone Pharmaceuticals2.5444 of 5 stars$2.00-1.5%$4.50+125.0%+30.7%$172.54M$1M-2.3830News CoveragePositive NewsAnalyst ForecastAVTXAvalo Therapeutics3.0158 of 5 stars$12.71-2.4%$31.67+149.1%+47.7%$171.24M$440K0.0040Gap UpTARAProtara Therapeutics1.9949 of 5 stars$4.35-1.4%$19.60+350.6%+191.4%$170.15MN/A-2.6930News CoveragePositive NewsAnalyst ForecastCTORCitius Oncology3.1252 of 5 stars$2.03flat$6.00+195.6%+78.6%$169.53MN/A0.00N/ANews CoverageAnalyst ForecastGap UpIPHAInnate Pharma2.6487 of 5 stars$1.93+6.0%$6.50+236.8%-7.0%$167.77M$21.77M0.00220Analyst ForecastGap UpNLTXNeoleukin TherapeuticsN/A$17.71-0.6%N/A-53.4%$166.44MN/A-5.6990High Trading VolumeSLSSELLAS Life Sciences Group2.2781 of 5 stars$1.61+3.2%$7.00+334.8%+58.2%$164.26M$1M-5.0310News CoveragePositive NewsAnalyst ForecastShort Interest ↓MCRBSeres Therapeutics2.4844 of 5 stars$19.24+2.9%$14.33-25.5%+27.3%$163.62M$126.32M-4.18330Positive NewsAnalyst Forecast Related Companies and Tools Related Companies FBRX Alternatives PLX Alternatives MIST Alternatives AVTX Alternatives TARA Alternatives CTOR Alternatives IPHA Alternatives NLTX Alternatives SLS Alternatives MCRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBRV) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
